All In Biotech

Drug Trial Radar · NCT06208150

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 838 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

838

Actual

Start

Jan 22, 2024

Primary completion

Apr 1, 2026

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

Conditions

  • Multiple Myeloma

Interventions

  • TalquetamabDrug

    Talquetamab will be administered as a SC injection.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

  • TeclistamabDrug

    Teclistamab will be administered as a SC injection.

  • ElotuzumabDrug

    Elotuzumab will be administered intravenously.

  • DexamethasoneDrug

    Dexamethasone will be administered either orally or intravenously.

  • BortezomibDrug

    Bortezomib will be administered as a SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 3 years 5 months

Locations

242 sites in 27 countries. Site status is shown where the registry gives one.

  • UCSF Fresno

    Clovis, California

  • UCLA

    Santa Monica, California

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Medical Oncology Hematology Consultants, PA

    Newark, Delaware

  • Memorial Healthcare System

    Hollywood, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute Emory University

    Atlanta, Georgia

  • City of Hope Cancer Center

    Newnan, Georgia

  • Kootenai Health

    Coeur d'Alene, Idaho

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Iowa Health Care

    Waukee, Iowa

  • Norton Cancer Institute

    Louisville, Kentucky

  • Our Lady of the Lake Hospital

    Baton Rouge, Louisiana

  • Luminis Health Center for Cancer and Blood Disorders

    Annapolis, Maryland

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Cancer Institute

    Detroit, Michigan

  • Henry Ford Health Providence Southfield Hospital

    Southfield, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Regions Hospital

    Saint Paul, Minnesota

  • University of Nebraska

    Omaha, Nebraska

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Weill Cornell Medical College

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • Louis Stokes Cleveland VA Med Ctr

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health And Science University

    Portland, Oregon

  • Penn State Milton S Hershey Medical Ctr

    Hershey, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • West Penn Hospital

    Pittsburgh, Pennsylvania

  • University Of Pittsburgh Medical Center UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Bon Secours Saint Francis Cancer Center

    Greenville, South Carolina

  • UT Southwestern Parkland Hospital

    Dallas, Texas

Showing 40 of 242 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.